Iniparib
Iniparib[edit | edit source]
Iniparib is a small molecule that was investigated as a potential anticancer drug. It was initially thought to be a PARP inhibitor, but subsequent studies suggested that its mechanism of action might be different from other drugs in this class.
Mechanism of Action[edit | edit source]
Iniparib was originally believed to inhibit poly (ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair. PARP inhibitors are a class of drugs that exploit the concept of synthetic lethality to target cancer cells, particularly those with BRCA1 or BRCA2 mutations. However, further research indicated that Iniparib might not function as a true PARP inhibitor, and its exact mechanism of action remains unclear.
Clinical Development[edit | edit source]
Iniparib was tested in several clinical trials for the treatment of triple-negative breast cancer (TNBC) and other types of cancer. Early-phase trials showed promising results, leading to its evaluation in larger, randomized studies.
Triple-Negative Breast Cancer[edit | edit source]
Triple-negative breast cancer is a subtype of breast cancer that lacks estrogen receptor, progesterone receptor, and HER2/neu expression. It is often more aggressive and has fewer treatment options compared to other breast cancer subtypes. Iniparib was studied in combination with chemotherapy agents such as gemcitabine and carboplatin in patients with TNBC.
Results and Challenges[edit | edit source]
While initial studies suggested potential benefits, subsequent phase III trials did not demonstrate a significant improvement in overall survival or progression-free survival when Iniparib was added to standard chemotherapy regimens. These results led to a reevaluation of its development as a cancer therapeutic.
Current Status[edit | edit source]
As of the latest updates, Iniparib is not approved for clinical use, and its development has been largely discontinued. The case of Iniparib highlights the challenges in drug development, particularly in understanding the precise mechanisms of action and the importance of robust clinical trial data.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
